“ Everything You Need to Know About Thyroid Cancer”
What Is Thyroid Cancer?
Thyroid cancer starts in your thyroid gland, a small, butterfly-shaped organ in the neck. Papillary and follicular types (differentiated thyroid cancers) account for most cases and boast excellent survival rates—over 99% five-year survival for papillary type.
Why Are Diagnoses Rising?
Incidence skyrocketed between the 1970s and 2009, primarily due to more imaging and needle biopsies detecting small nodules that may never cause problems . Though rates stabilized after 2009, overdiagnosis remains a pressing concern .
Modern Diagnostic Tools
Advanced ultrasound imaging, radiomics, molecular testing, and AI are enhancing accuracy. A 2024 review found AI improved diagnostic precision but still needs standardization.
Cutting‑Edge Treatments
- CAR‑T cell therapy (AIC100) showed promising early results in aggressive thyroid cancers like anaplastic and poorly differentiated types, achieving tumor control for over half of patients.
- Targeted and immunotherapy combinations, especially those addressing BRAF mutations, doubled median survival in anaplastic cases from 5 to 19 months.
- RET‑inhibiting drugs—such as selpercatinib and pralsetinib—are FDA-approved for advanced RET-mutated thyroid cancers.
Who’s at Higher Risk?
People with genetic syndromes (e.g. MEN2), family history, or past radiation exposure are more at risk. GLP‑1 diabetes meds (Ozempic/Wegovy) are linked to more thyroid scans—not cancer—due to increased screening.
Key Takeaways
Thyroid cancer is often treatable—especially papillary and follicular types.
Overdiagnosis from imaging can lead to unnecessary treatment.
New molecular and immunotherapies offer hope for advanced cases.
If diagnosed, discuss active surveillance vs. surgery based on risk.
Supporting Sources
Latest news:
- Ozempic links to overdiagnosis via screening
- High-profile diagnoses: Shari Redstone confirms thyroid cancer
Research & clinical trials:
- CAR‑T therapy (AIC100) Phase I data
- AI in radiomics and diagnostics
- Immunotherapy + targeted therapy in anaplastic cancer
- RET‑targeted drugs (selpercatinib, pralsetinib)
- Overdiagnosis trends in U.S.